| Management target | Revenue 17.5% |
|---|
| Revenue growth | 3.93% YoY for Q1 FY27. |
|---|---|
| Margins | EBITDA margin improved to 9.99% from 7.34% YoY. |
| Demand visibility | Strong regulated market pipeline; USFDA/EU GMP clearances secured. |
| Management confidence | High; citing confident opening note for FY27. |
Growth
Revenue reached ₹193.81 Cr; EBITDA rose 41.56% YoY to ₹19.36 Cr; PAT surged 37.63% YoY to ₹11.42 Cr.
Outlook
Management anticipates 15-20% per annum steady growth; four new products under development including Vonoprazon Fumarate and Edoxaban Tosylate.
Risks
Currency risk cited; management is diversifying export markets to mitigate impact. Competitive intensity in generic APIs remains.
Investor Presentation filed with BSE, NSE: ANUHPHR. Summary written with AI assistance from the document.
Anuh Pharma Ltd: key numbers
- Share price
- ₹85.51
- Market cap
- ₹857.0 Cr
- Revenue (annual)
- ₹771.7 Cr
- Net profit (annual)
- ₹41.05 Cr
- P/E (TTM)
- 19.4×Sector 47.3×
- Promoter holding
- 71.80%+0.00% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anuh Pharma Ltd
All →Anuh Pharma Legal & Regulatory
Anuh Pharma disclosed a Rs. 9,93,206 tax demand under Section 156, Income Tax Act, for AY 2018-19. The company plans to appeal before the CIT.
- Value
- ₹0.10 Cr
Anuh Pharma Management Change
Anuh Pharma announced the re-appointment of directors Arun Lalchand Todarwal and Bipin N. Shah, and the appointment of Ankit Kishor Chande as Cost Auditor.
Anuh Pharma Annual General Meeting
Anuh Pharma Ltd held its 66th Annual General Meeting on August 12, 2026. The meeting covered the adoption of financial statements, dividend declaration, and director appointments.
Anuh Pharma Other Announcement
Anuh Pharma Ltd. promoters withdrew their application for reclassification from 'Promoter Group' to 'Public' category. They will continue to remain part of the Promoter Group.
Anuh Pharma Q1 FY27 Results: Net Profit ₹11.4 Cr, Up 37.3% YoY
Anuh Pharma Ltd reported revenue from operations of ₹193.8 Cr (+3.9% YoY) and net profit of ₹11.4 Cr (+37.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹11.4 Cr · +37.3% YoY
Anuh Pharma Board Meeting Date
Anuh Pharma Ltd has scheduled a board meeting for August 7, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.